Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Germany17753704.0Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Czech Republic17753704.0Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Switzerland17753704.0Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Belgium17753704.0Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Austria17753704.0Filed on 2017-02-14
ADAM17 BINDING MOLECULES AND USES THEREOF Read more about ADAM17 BINDING MOLECULES AND USES THEREOF European Patent20769619.6Filed on 2020-03-07
Chimeric Antigen Receptors Containing Glypican 2 Binding Domains Read more about Chimeric Antigen Receptors Containing Glypican 2 Binding Domains Japan2022-503413Filed on 2020-07-17
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION Read more about HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION Russia2022124004Filed on 2021-02-12
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION Read more about HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION Cuba2022-0044Filed on 2021-02-12
COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF CERVICAL CANCER AND CERVICAL INTRAEPITHELIAL NEOPLASIA Read more about COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF CERVICAL CANCER AND CERVICAL INTRAEPITHELIAL NEOPLASIA US Patent 11,905,564Filed on 2022-08-01